New hope for bile duct cancer: maintenance therapy trial launches
NCT ID NCT07269158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced biliary tract cancer whose disease is stable after initial chemotherapy plus immunotherapy. It compares four different maintenance treatments: immunotherapy alone or combined with lenvatinib, venadaparib, or interleukin-2. The goal is to find which combination works best to keep the cancer from growing and improve survival. About 160 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine, Korea
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a targeted antibody boost chemotherapy for a rare bile duct cancer?
- Can a cancer vaccine train the body to fight advanced tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures